Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | HRH2 | P25021 | 2/20 | 0.34 |
| ▸ | HRH1 | P35367 | 2/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2479999 | 0.82 | LMNA (0.45) | LMNAPOLBSMN1; SMN2HRH2HRH1 | |
| SCHEMBL533925 | 0.82 | LMNA (0.45) | LMNAPOLBSMN1; SMN2HRH2HRH1 | |
| SCHEMBL1445031 | 0.81 | LMNA (0.48) | LMNAPOLBSMN1; SMN2PTGDR2HRH2 | |
| SCHEMBL10097950 | 0.81 | LMNA (0.48) | LMNAPOLBSMN1; SMN2PTGDR2HRH2 | |
| SCHEMBL29574427 | 0.80 | SMN1; SMN2 (0.42) | LMNAPOLBSMN1; SMN2PTGDR2HRH2 | |
| SCHEMBL29598912 | 0.79 | LMNA (0.49) | LMNAPOLBSMN1; SMN2PTGDR2HRH2 | |
| SCHEMBL2260180 | 0.79 | LMNA (0.39) | LMNAPOLBSMN1; SMN2HRH2HRH1 | |
| SCHEMBL1007010 | 0.78 | DDB1 (0.40) | SMN1; SMN2KDM4E | |
| SCHEMBL15166573 | 0.78 | LMNA (0.48) | LMNAPOLBSMN1; SMN2PTGDR2HRH2 | |
| SCHEMBL31722736 | 0.77 | LMNA (0.47) | LMNAPOLBSMN1; SMN2PTGDR2HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRM1, GRIK1 | LMNA 4015/4885POLB 3571/4885SMN1; SMN2 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.